Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 31, 2018 - Issue 3
Submit an article Journal homepage
23
Views
3
CrossRef citations to date
0
Altmetric
Case Studies

Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy

Laurie JanskyDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas
, MD,
Pallavi MukkamalaDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas
, MD,
Deborah JebakumarDepartment of Pathology, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas
, MD,
Arundhati RaoDepartment of Pathology, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas
, MD, PhD,
Tove M. GoldsonDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas
, MD, PhD &
Samuel N. ForjuohDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, TexasCorrespondence[email protected]
, MD, MPH, DrPH
Pages 321-323 | Received 22 Nov 2017, Accepted 02 Apr 2018, Published online: 09 May 2018

  • Blommel MM, Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011;68:1506–1519. doi:10.2146/ajhp100348.
  • Boehringer Ingelheim. US FDA approves Pradaxa (dabigatran etexilate—a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation [press release]. October 20, 2010. https://www.businesswire.com/news/home/20101020005862/en/FDA-Approves-Pradaxa%C2%AE-dabigatran-etexilate-%E2%80%93-breakthrough. Accessed March 28, 2018.
  • Escoli R, Santos P, Andrade S, Carvalho F. Dabigatran-related nephropathy in a patient with undiagnosed IgA nephropathy. Case Rep Nephrol. 2015;2015:298261. doi:10.1155/2015/298261.
  • Ryan M, Ware K, Qamri Z, et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant. 2014;29:2228–2234. doi:10.1093/ndt/gft380.
  • Martin Cleary C, Moreno JA, Fernandez B, et al. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant. 2010;25:4103–4106. doi:10.1093/ndt/gfq493.
  • Gois M, Azevedo A, Carvalho F, Nolasco F. Anticoagulant-related nephropathy in a patient with IgA nephropathy. BMJ Case Rep. 2017. pii:bcr2016218748. doi:10.1136/bcr-2016-218748.
  • Shafi ST, Negrete H, Roy P, Julius CJ, Sarac E. A case of dabigatran-associated acute renal failure. WMJ. 2013;112(4):173–175.
  • Moeckel GW, Luciano RL, Brewster UC. Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin. Clin Kidney J. 2013;6:507–509. doi:10.1093/ckj/sft076.
  • Kalaitzidis RG, Duni A, Liapis G, et al. Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity. Int Urol Nephrol. 2017;49:1401–1407. doi:10.1007/s11255-017-1527-9.
  • Chan YH, Yeh YH, See LC, et al. Acute kidney injury in Asians with atrial fibrillation treated with dabigatran or warfarin. J Am Coll Cardiol. 2016;68:2272–2283. doi:10.1016/j.jacc.2016.08.063.
  • Spinler S. The pharmacology and therapeutic use of dabigatran etexilate. J Clin Pharmacol. 2013;53:1–13. doi:10.1177/0091270011432169.
  • Lexicomp. Dabigatran etexilate. Wolters Kluwer Clinical Drug Information, Inc.; 2017. Accessed April 8, 2017.
  • Asinger RW, Shroff GR. Atrial fibrillation and renal function: how high is the price of anticoagulation? J Am Coll Cardiol. 2015;65:2494–2495. doi:10.1016/j.jacc.2015.04.043.
  • Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65:2481–2493. doi:10.1016/j.jacc.2015.03.577.
  • Goriacko P, Yaghdjian V, Koleilat I, Sinnett M, Shukla H. The use of idarucizumab for dabigatran reversal in clinical practice: a case series. P T. 2017;42:699–703.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.